Related Experiment Video
Updated: Aug 9, 2026

Enrichment of mRNA and Bisulfite-mRNA Library Preparation for Next-Generation Sequencing
Published on: July 7, 2023
IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer
Sandra Margielewska-Davies1, Wayne Croft1, Hayden Pearce1
1School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Abstract:
The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing but clinical outcomes remain poor and new treatments are required. IGF2BP3 is an oncofetal m6A-reading RNA regulatory protein whose expression is commonly observed in PDAC and which may represent an important therapeutic target. IGF2BP3 protein is expressed in >95% of primary tumours whilst RNA expression ranges from 3 to 3000-fold above normal epithelium. siRNA knockdown reveals IGF2BP3 to strongly support expression of gene programs related to DNA replication, cell cycle and apoptosis, TNF signalling and epithelial-mesenchymal transition. Direct sequencing of native RNA further reveals IGF2BP3-mediated enhancement of 863 RNA isoforms with suppression of 389 isoforms. m6A, m5C and pseudouridine (ψ) RNA modifications were seen in 97% of transcripts within the PDAC transcriptome and enriched within MYC gene targets. IGF2BP3 regulated the pattern of RNA modification with a substantial impact on m5C modifications of miRNA and scRNA, and genes associated with regulation of TNF signalling. Knockdown of IGF2BP3 expression in primary tumour organoid cultures suppressed proliferation and elicited apoptosis, indicating a critical requirement for IGF2BP3 within malignant stem cells. These data show that IGF2BP3 is expressed consistently in PDAC, plays a dominant role in regulation of RNA splicing and modification, and supports cancer stem cell proliferation and survival. IGF2BP3 therefore occupies a critical position within the RNA regulon of PDAC and represents an important therapeutic target in this tumour of unmet need.
Insights
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is crucial for pancreatic ductal adenocarcinoma (PDAC) progression. Targeting IGF2BP3 may offer a new therapeutic strategy for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- RNA Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) incidence is rising with poor clinical outcomes.
- IGF2BP3, an oncofetal RNA regulatory protein, is highly expressed in PDAC and a potential therapeutic target.
Purpose of the Study:
- To investigate the role of IGF2BP3 in PDAC progression and its potential as a therapeutic target.
Main Methods:
- siRNA knockdown of IGF2BP3 in PDAC cells and organoids.
- Direct RNA sequencing to analyze IGF2BP3-mediated RNA splicing and modification.
- Analysis of RNA modifications (m6A, m5C, pseudouridine) in PDAC transcriptome.
Main Results:
- IGF2BP3 knockdown suppressed PDAC cell proliferation, DNA replication, cell cycle, TNF signaling, and epithelial-mesenchymal transition.
- IGF2BP3 significantly altered RNA splicing and modification patterns, impacting miRNA and scRNA.
- IGF2BP3 is essential for malignant stem cell proliferation and survival in PDAC organoids.
Conclusions:
- IGF2BP3 consistently expressed in PDAC, plays a dominant role in RNA regulation.
- IGF2BP3 supports PDAC stem cell survival and proliferation, making it a critical therapeutic target.
Related Concept Videos
Regulation of Expression at Multiple Steps
Experimental RNAi
MicroRNAs
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Leaky Scanning
What is Gene Expression?